Knight Therapeutics Inc. (TSX:GUD)
Canada · Delayed Price · Currency is CAD 8.19
+0.24 (3.02%)
May 29, 2026, 4:00 PM EST
Knight Therapeutics Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 510.45 | 450.09 | 371.3 | 328.2 | 293.56 | 243.48 | |
Revenue Growth (YoY) | 36.93% | 21.22% | 13.13% | 11.80% | 20.57% | 22.03% |
Cost of Revenue | 275.98 | 249.86 | 196.9 | 175.55 | 155.5 | 128.07 |
Gross Profit | 234.47 | 200.23 | 174.41 | 152.65 | 138.06 | 115.41 |
Selling, General & Admin | 132.41 | 124.11 | 99.35 | 83.69 | 88.62 | 74.38 |
Depreciation & Amortization Expenses | 54.69 | 49.49 | 44.36 | 45.04 | 51.74 | 41.18 |
Research & Development | 33.61 | 28.98 | 23.3 | 17.55 | 14.76 | 12.69 |
Other Operating Expenses | - | - | - | 9.26 | 23.98 | - |
Total Operating Expenses | 220.71 | 202.58 | 167.01 | 155.54 | 179.11 | 128.24 |
Operating Income | 13.77 | -2.35 | 7.4 | -2.89 | -41.04 | -12.83 |
Interest Income | 5.3 | 6.21 | 10.41 | 12.58 | 10.63 | 7.38 |
Interest Expense | -11.31 | -10.42 | -9.22 | -12.49 | -6.6 | -3.62 |
Other Non-Operating Income (Expense) | 0.12 | -0.14 | -6.53 | -19.19 | -6.95 | 15.76 |
Total Non-Operating Income (Expense) | -5.89 | -4.35 | -5.35 | -19.1 | -2.92 | 19.52 |
Pretax Income | 7.88 | -6.7 | 2.05 | -21.99 | -43.96 | 6.69 |
Provision for Income Taxes | -2.23 | 0 | 0 | 0 | 0 | 0 |
Net Income | 5.61 | -5.37 | 4.33 | -16.84 | -29.89 | -15.68 |
Net Income to Common | 5.61 | -5.37 | 4.33 | -16.84 | -29.89 | -15.68 |
Net Income Growth | -49.29% | - | - | - | - | - |
Shares Outstanding (Basic) | 99 | 100 | 101 | 107 | 115 | 124 |
Shares Outstanding (Diluted) | 100 | 100 | 101 | 107 | 115 | 125 |
Shares Change (YoY) | -1.34% | -1.84% | -5.61% | -6.46% | -7.74% | -5.65% |
EPS (Basic) | 0.05 | -0.05 | 0.04 | -0.16 | -0.26 | 0.13 |
EPS (Diluted) | 0.05 | -0.05 | 0.04 | -0.16 | -0.26 | 0.13 |
EPS Growth | -54.41% | - | - | - | - | -59.38% |
Shares Outstanding | 98.25 | 99.18 | 100.03 | 101.17 | 112.21 | 117.78 |
Free Cash Flow | 101.12 | 67.05 | 33.81 | 34.99 | 42.12 | 40.79 |
Free Cash Flow Growth | 50.81% | 98.30% | -3.37% | -16.92% | 3.26% | - |
Free Cash Flow Per Share | 1.02 | 0.67 | 0.33 | 0.33 | 0.37 | 0.33 |
Gross Margin | 45.93% | 44.49% | 46.97% | 46.51% | 47.03% | 47.40% |
Operating Margin | 2.70% | -0.52% | 1.99% | -0.88% | -13.98% | -5.27% |
Profit Margin | 1.10% | -1.19% | 1.17% | -5.13% | -10.18% | -6.44% |
FCF Margin | 19.81% | 14.90% | 9.11% | 10.66% | 14.35% | 16.75% |
EBITDA | 74.94 | 54.22 | 60.51 | 47.51 | 21.58 | 35.08 |
EBITDA Margin | 14.68% | 12.05% | 16.30% | 14.48% | 7.35% | 14.41% |
EBIT | 13.77 | -2.35 | 7.4 | -2.89 | -41.04 | -12.83 |
EBIT Margin | 2.70% | -0.52% | 1.99% | -0.88% | -13.98% | -5.27% |
Effective Tax Rate | -28.28% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |